Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

Aziz Nazha, Mayur Narkhede, Tomas Radivoyevitch(Cleveland Clinic), David J. Seastone, Bhumika J. Patel(Cleveland Clinic), Aaron T. Gerds, S. Mukherjee, M Kalaycio, Anjali S. Advani, B Przychodzen(Cleveland Clinic), Hetty E. Carraway, Jaroslaw P. Maciejewski(Cleveland Clinic), Mikkael A. Sekeres

Leukemia

May 20, 2016

10.1038/leu.2016.138

Cited by 151

Abstract

Related Papers

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau et al.|Blood|1997|4.5k

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

James W. Vardiman, Jüergen Thiele, Daniel A. Arber et al.|Blood|2009|4.4k

Clinical and biological implications of driver mutations in myelodysplastic syndromes

Elli Papaemmanuil, Moritz Gerstung, Luca Malcovati et al.|Blood|2013|1.8k

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

Rafael Bejar, Kristen E. Stevenson, Omar Abdel‐Wahab et al.|New England Journal of Medicine|2011|1.6k

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

Torsten Haferlach, Yasunobu Nagata, Vera Grossmann et al.|Leukemia|2013|1.5k